Becton, Dickinson and Company Share Price Xetra

Equities

BOX

US0758871091

Medical Equipment, Supplies & Distribution

Market Closed - Xetra 09:05:33 28/06/2024 pm IST 5-day change 1st Jan Change
218.7 EUR +1.25% Intraday chart for Becton, Dickinson and Company -2.06% +0.32%

Financials

Sales 2024 * 20.25B 18.9B 1,687B Sales 2025 * 21.42B 20B 1,785B Capitalization 67.54B 63.06B 5,629B
Net income 2024 * 2.09B 1.95B 175B Net income 2025 * 2.48B 2.31B 207B EV / Sales 2024 * 3.98 x
Net Debt 2024 * 13.13B 12.26B 1,094B Net Debt 2025 * 10.8B 10.08B 900B EV / Sales 2025 * 3.66 x
P/E ratio 2024 *
32.8 x
P/E ratio 2025 *
29.1 x
Employees 73,000
Yield 2024 *
1.61%
Yield 2025 *
1.64%
Free-Float 77.74%
More Fundamentals * Assessed data
Dynamic Chart
BD (Becton, Dickinson and Company) Announces the Commercial Launch of a New Single-Cell Research Tool CI
Tandem Diabetes Care, Inc. Appoints Jean-Claude Kyrillos as Executive Vice President and Chief Operating Officer, Effective June 21, 2024 CI
Evercore ISI Raises Becton, Dickinson and Company's Price Target to $290 From $282 MT
Sector Update: Health Care Stocks Steady Premarket Monday MT
Becton Dickinson to Acquire Edwards Lifesciences' Critical Care Product Group for $4.2 Billion in Cash DJ
Becton, Dickinson to Acquire Edwards Lifesciences' Critical Care Product Division for $4.2 Billion in Cash MT
Edwards Lifesciences to sell critical care products unit to Becton Dickinson for $4.2 bln RE
Becton, Dickinson to Acquire Edwards Lifesciences' Critical Care Product Group for $4.2 Billion MT
Becton, Dickinson and Company entered into an agreement to acquire Critical Care Product Group of Edwards Lifesciences Corporation (NYSE : EW) for $4.2 billion. CI
DBS Bank Adjusts Price Target on Becton, Dickinson to $285 From $300 MT
Transcript : Becton, Dickinson and Company Presents at Bank of America Health Care Conference 2024, May-14-2024 08:00 AM
Exclusive-Biden to put tariffs on China medical supplies - sources RE
Barclays Adjusts Price Target on Becton, Dickinson to $312 From $305, Keeps Overweight Rating MT
TD Cowen Adjusts Price Target on Becton, Dickinson and Company to $260 From $271 MT
Evercore ISI Raises Becton, Dickinson and Company Price Target to $282 From $280 MT
More news
1 day+1.25%
1 week-2.06%
Current month+3.16%
1 month+4.54%
3 months-4.29%
6 months-0.59%
Current year+0.32%
More quotes
1 week
216.00
Extreme 216
223.50
1 month
206.90
Extreme 206.9
224.90
Current year
206.90
Extreme 206.9
232.60
1 year
206.90
Extreme 206.9
263.50
3 years
202.30
Extreme 202.3
265.45
5 years
194.80
Extreme 194.8
265.45
10 years
194.80
Extreme 194.8
265.45
More quotes
Managers TitleAgeSince
Chief Executive Officer 50 01/09/01
Director of Finance/CFO 52 06/21/06
Chief Tech/Sci/R&D Officer 48 01/19/01
Members of the board TitleAgeSince
Director/Board Member 73 24/02/24
Director/Board Member 73 29/13/29
Director/Board Member 69 26/10/26
More insiders
Date Price Change Volume
28/24/28 218.7 +1.25% 1
27/24/27 216 -0.69% 1
26/24/26 217.5 -0.64% 1
25/24/25 218.9 -1.17% 1
24/24/24 221.5 -0.81% 1

Delayed Quote Xetra, June 28, 2024 at 09:05 pm IST

More quotes
Becton, Dickinson and Company specializes in the development, manufacturing and marketing of medical and diagnostic equipment and materials. Net sales break down by family of products as follows: - medical equipment (73.5%): surgical instruments, urological care products, pharmaceutical systems, etc.; - diagnostic materials (18.7%): automated systems for blood testing, mycobacteria detection, and molecular biology, medical biology devices, etc.; - clinical research and development tools (7.8%): tools for discovering drugs and vaccines, studying genes, culturing cells, and manipulating liquids, instruments for sorting and analyzing cells, monoclonal antibodies, etc. Net sales are distributed geographically as follows: the United States (57.4%), Europe/Middle East/Africa (21.9%), Asia (15%) and other (5.7%).
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
233.7 USD
Average target price
279.2 USD
Spread / Average Target
+19.46%
Consensus